Date: 2017-02-21
Type of information: Establishment of a new subsidiary in the US
Compound: canadian subsidiary
Company: Cardiabase by Banook Group (France)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary
Action mechanism:
Disease:
Details: * On February 21, 2017, the Banook Group, global provider of cardiac safety, central imaging and endpoint adjudication services for clinical trials, announced that it has opened a new subsidiary at the Neomed Institute, a center of excellence in clinical research, in Montreal, Canada. The new subsidiary will strengthen the Banook Group’s presence in North America, which already accounts for 25% of its turnover. With this subsidiary the company is aiming foran average growth of 30% by 2018. The launch of a Canadian subsidiary reflects the ongoing commitment of the Banook Group to maximizing value for its customers; providing superior support based on a “follow the sun” model (tasks are passed around daily between work sites to cover many time zones). The Banook Group has offices in Nancy (France) and already has a long track record with numerous North American large pharma and biotech companies. The company plans to attend several conferences in North America in 2017, including DIA in Chicago in June. The Banook Group also expects to set up partnerships with local specialized companies.
Financial terms:
Latest news:
